title: [Cognitive rehabilitation in Alzheimer's disease patients: multidisciplinary team report].
abstract: OBJECTIVE
  This study aims to show preliminary results of the 'combined treatment' (acetylcholinesterase inhibitor + cognitive training) on a group of mild Alzheimer's disease (AD) patients, followed-up for 7 months.
  
  
  METHODS
  Six mild AD patients, diagnosed according to ICD-10 and NINCDS-ADRDA criteria, were included on a open trial with Rivastigmine, 6-12 mg/day, for 2 months, followed by a weekly cognitive rehabilitation group, for 5 months. Caregivers were submitted to a weekly group of counseling and support for 5 months.
  
  
  RESULTS
  Stabilization or mild improvement of patients' cognitive and activities of daily living deficits were found, besides reduction of patients and caregivers' depressive and anxiety levels.
  
  
  CONCLUSIONS
  The 'combined treatment' can help on the stabilization or result on a mild improvement of AD patients' cognitive and functional deficits. Support and counseling interventions can reduce the levels of caregivers' psychiatric symptoms.
authors.affiliation: Instituto de Psiquiatria, Hospital das Clínicas, Faculdade de Medicina, Universidade de São Paulo, Brasil. cbottino@usp.br
authors.forename: Cássio M C
authors.initials: CM
authors.lastname: Bottino
authors.forename: Isabel A M
authors.initials: IA
authors.lastname: Carvalho
authors.forename: Ana Maria M A
authors.initials: AM
authors.lastname: Alvarez
authors.forename: Renata
authors.initials: R
authors.lastname: Avila
authors.forename: Patrícia R
authors.initials: PR
authors.lastname: Zukauskas
authors.forename: Sonia E Z
authors.initials: SE
authors.lastname: Bustamante
authors.forename: Flávia C
authors.initials: FC
authors.lastname: Andrade
authors.forename: Sérgio R
authors.initials: SR
authors.lastname: Hototian
authors.forename: Fabiana
authors.initials: F
authors.lastname: Saffi
authors.forename: Cândida H P
authors.initials: CH
authors.lastname: Camargo
mesh_terms: D000203:Activities of Daily Living; D000368:Aged; D000369:Aged, 80 and over; D000544:Alzheimer Disease / Q000188:drug therapy / Q000628:therapy*; D002219:Carbamates / Q000627:therapeutic use*; D017028:Caregivers / Q000523:psychology; D002800:Cholinesterase Inhibitors / Q000627:therapeutic use*; D003072:Cognition Disorders / Q000188:drug therapy / Q000534:rehabilitation*; D003131:Combined Modality Therapy; D005260:Female; D006801:Humans; D008297:Male; D008875:Middle Aged; D009483:Neuropsychological Tests; D010348:Patient Care Team; D048448:Phenylcarbamates; D000068836:Rivastigmine
chemical_list: D002219:Carbamates; D002800:Cholinesterase Inhibitors; D048448:Phenylcarbamates; D000068836:Rivastigmine